Send to

Choose Destination
Mol Cell Proteomics. 2020 Jan 10. pii: mcp.RA119.001905. doi: 10.1074/mcp.RA119.001905. [Epub ahead of print]

Integration Of IgA and IgG Autoantigens Improves Performance Of Biomarker Panels For Early Diagnosis Of Lung Cancer.

Author information

Johns Hopkins University School of Medicine, United States of America.
Provincial Clinical College, Fujian Medical University, China.
Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, United States of America.
CDI Laboratories Inc.
CDI Laboratories, Inc., Mayaguez, United States of America.
CDI Laboratories.
Dept of Pharmacology & HiT Center, Johns Hopkins Medical Institute, United States of America.
Kimmel Cancer Center.
Provincial Clinical College, Fujian Medical University, China


Lung cancer (LC) remains the leading cause of mortality from malignant tumors worldwide. In our previous study, we surveyed both IgG and IgM-bound serological biomarkers and validated a panel of IgG-bound autoantigens for early LC diagnosis with 50% sensitivity at 90% specificity. To further improve the performance of these serological biomarkers, we surveyed HuProt arrays, comprised of 20, 240 human proteins, for IgA-bound autoantigens since IgAs are a major immunoglobulin isotype in the lung. Integrating with IgG-bound autoantigens, we discovered and validated a combined biomarker panel using ELISA-format tests. Specifically, in Phase I, we obtained IgA-based autoimmune profiles of 69 early stage LC patients, 30 healthy subjects and 25 patients with lung benign lesions (LBL) on HuProt arrays, and identified 28 proteins as candidate autoantigens that were significantly associated with early stage LC. In Phase II, we re-purified the autoantigens and converted them into an ELISA-format testing to profile an additional large cohort, comprised of 136 early stage LC patients, 58 healthy individuals, and 29 LBL patients. Integration of IgG autoimmune profiles allowed us to identify and validate a biomarker panel of three IgA autoantigens (i.e., BCL7A, and TRIM33 and MTERF4) and three IgG autoantigens (i.e., CTAG1A, DDX4 and MAGEC2) for diagnosis of early stage LC with 73.5% sensitivity at >85% specificity. In Phase III, the performance of this biomarker panel was confirmed with an independent cohort, comprised of 88 early stage LC patients, 18 LBL patients, and 36 healthy subjects. Finally, a blind test on 178 serum samples was conducted to confirm the performance of the biomarker panel. In summary, this study demonstrates for the first time that an integrated panel of IgA/IgG autoantigens can serve as valuable biomarkers to further improve the performance of early diagnosis of LC.


Cancer biomarker(s); ELISA; Early diagnosis; High Throughput Screening; HuProt array; Lung cancer; Protein array; caner early diagnosis; serological biomarkers

Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center